Matthew Baumgardner

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 176 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor

Lichuan Liu, Jason Halladay, Young G. Shin et al. · Drug Metabolism and Disposition · 2011 · 74 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479

Kirk Robarge, Wendy Lee, Charles Eigenbrot et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

Alan G. Olivero, Timothy P. Heffron, Matthew Baumgardner et al. · Cancer Research · 2013 · 15 citations

Pharmacy, Oncology, Pharmacology +14